Fortitude Family Office’s Vanda Pharmaceuticals VNDA Stock Holding History

Fortitude Family Office’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$398	Buy	+65	New	+$425	﹤0.01%	2013

Other funds holding VNDA

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Nations Financial Group Cedar Rapids, Iowa $2.09B AUM 34.27% 1-Year Est. Return

NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Capital Advisors Ltd Shaker Heights, Ohio $991M AUM 19.82% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Fortitude Family Office's VNDA Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2026: 65 shares worth $398. The stake represents ﹤0.01% of the portfolio and ranks #2013 among its holdings.

24 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Fortitude Family Office held 65 shares of Vanda Pharmaceuticals worth $398 as of Q2 2026.
Vanda Pharmaceuticals was a new Fortitude Family Office position in Q2 2026.
Vanda Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2013 holding.
24 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.